SCHEMBL1765360

SCHEMBL1765360

CCOC(=O)c1cc(-c2cc(F)cc(OC)c2)n(-c2cccc(Cl)c2)n1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC16A3 O15427 2/20 0.52
SLC16A1 P53985 2/20 0.52
TP53 P04637 2/20 0.50
LMNA P02545 1/20 0.50
FAAH O00519 5/20 0.49
CHRNA7 P36544 3/20 0.49
MGLL Q99685 2/20 0.49
POLB P06746 1/20 0.48
CCKAR P32238 1/20 0.48
ALDH1A1 P00352 1/20 0.47
PPP1CA P62136 1/20 0.47
MCTS1 Q9ULC4 1/20 0.47
CA9 Q16790 1/20 0.46
GABRA2 P47869 1/20 0.46
GABRB2 P47870 1/20 0.46
THRB P10828 1/20 0.46
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1764994 0.92 TP53 (0.55) TP53LMNAFAAHCHRNA7MGLL
SCHEMBL1764878 0.90 TP53 (0.53) TP53LMNAFAAHCHRNA7MGLL
SCHEMBL1764893 0.90 CHRNA7 (0.51) TP53FAAHCHRNA7MGLLPOLB
SCHEMBL1765003 0.89 TP53 (0.52) TP53LMNAFAAHCHRNA7MGLL
SCHEMBL1765509 0.88 CCKAR (0.60) SLC16A3SLC16A1TP53LMNAFAAH
SCHEMBL1765022 0.87 PPP1CA (0.63) SLC16A3SLC16A1CCKARPPP1CAMCTS1
SCHEMBL1765268 0.86 LMNA (0.49) TP53LMNAFAAHCHRNA7MGLL
SCHEMBL1764971 0.85 TP53 (0.48) TP53LMNAFAAHCHRNA7MGLL
SCHEMBL3428152 0.85 SLC16A3 (0.50) SLC16A3SLC16A1TP53LMNAFAAH
SCHEMBL1765356 0.84 FAAH (0.56) TP53FAAHCHRNA7MGLLPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-8399682-B2 Substituted (pyrazolylcarbonyl)imidazolidinones and their use AICURIS GMBH & CO. KG (DE) 2013-03-19 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE AICURIS GMBH & CO. KG (DE) 2011-05-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124618-A1 SUBSTITUTED (PYRAZOLYLCARBONYL)IMIDAZOLIDINONES AND THEIR USE TPMT, PAICS, THPO SLC16A3 2453/4885SLC16A1 2093/4885TP53 1099/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.